1. Home
  2. VECO vs DFTX Comparison

VECO vs DFTX Comparison

Compare VECO & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veeco Instruments Inc.

VECO

Veeco Instruments Inc.

HOLD

Current Price

$34.25

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.70

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VECO
DFTX
Founded
1945
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
VECO
DFTX
Price
$34.25
$20.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$27.25
$40.25
AVG Volume (30 Days)
976.1K
1.6M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.59
N/A
Revenue
$664,294,000.00
N/A
Revenue This Year
$16.39
N/A
Revenue Next Year
$12.40
N/A
P/E Ratio
$58.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.92
$14.62
52 Week High
$37.23
$21.10

Technical Indicators

Market Signals
Indicator
VECO
DFTX
Relative Strength Index (RSI) 56.20 65.59
Support Level $27.99 $16.41
Resistance Level $36.50 N/A
Average True Range (ATR) 1.87 1.08
MACD 0.19 0.21
Stochastic Oscillator 59.86 89.53

Price Performance

Historical Comparison
VECO
DFTX

About VECO Veeco Instruments Inc.

Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The maximum of the company's revenue is generated from sales to the Semiconductor Industry and within China.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: